SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Ajanta Pharma - Quaterly Results

28 Jul 2022 Evaluate
A fair growth of 14.48% in the revenue at Rs. 8502.90 millions was reported in the June 2022 quarter as compared to Rs. 7427.20 millions during year-ago period.A slender decline of -22.27% was recorded to Rs. 1503.70  millions from Rs. 1934.60 millions in the corresponding previous quarter.The Operating Profit of the company witnessed a decrease to 2217.30 millions from 2640.20 millions.


(Rs. in Million)


  Quarter ended Year to Date Year ended
  202206 202106 % Var 202206 202106 % Var 202203 202103 % Var
Sales 8502.90 7427.20 14.48 8502.90 7427.20 14.48 31406.40 27185.90 15.52
Other Income 354.20 310.00 14.26 354.20 310.00 14.26 1397.30 1035.70 34.91
PBIDT 2217.30 2640.20 -16.02 2217.30 2640.20 -16.02 10306.20 10204.80 0.99
Interest 6.30 11.70 -46.15 6.30 11.70 -46.15 91.20 69.00 32.17
PBDT 2211.00 2628.50 -15.88 2211.00 2628.50 -15.88 10215.00 10135.80 0.78
Depreciation 307.50 297.60 3.33 307.50 297.60 3.33 1209.60 1114.90 8.49
PBT 1903.50 2330.90 -18.34 1903.50 2330.90 -18.34 9005.40 9020.90 -0.17
TAX 399.80 396.30 0.88 399.80 396.30 0.88 1806.80 2264.50 -20.21
Deferred Tax -18.30 32.60 -156.13 -18.30 32.60 -156.13 95.10 97.70 -2.66
PAT 1503.70 1934.60 -22.27 1503.70 1934.60 -22.27 7198.60 6756.40 6.54
Equity 257.10 173.90 47.84 257.10 173.90 47.84 171.70 173.90 -1.27
PBIDTM(%) 26.08 35.55 -26.64 26.08 35.55 -26.64 32.82 37.54 -12.58

Ajanta Pharma Share Price

2790.15 -37.95 (-1.34%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×